Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $34.20 USD
Change Today +0.17 / 0.50%
Volume 1.1M
SGEN On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

seattle genetics inc (SGEN) Snapshot

Open
$34.27
Previous Close
$34.03
Day High
$35.26
Day Low
$33.88
52 Week High
08/28/14 - $44.95
52 Week Low
01/16/15 - $30.05
Market Cap
4.3B
Average Volume 10 Days
1.0M
EPS TTM
$-0.66
Shares Outstanding
124.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SEATTLE GENETICS INC (SGEN)

seattle genetics inc (SGEN) Related Businessweek News

View More BusinessWeek News

seattle genetics inc (SGEN) Details

Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Its lead product, ADCETRIS (brentuximab vedotin), is an ADC that is commercially available in approximately 50 countries, including the United States, Canada, Japan, and members of the European Union for relapsed Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL) in collaboration with Takeda Pharmaceutical Company Limited. The company is evaluating ADCETRIS in approximately 30 ongoing clinical trials, including Phase III trials for post-transplant HL relapse prevention, relapsed CD30-positive cutaneous T-cell lymphoma, frontline HL in combination with chemotherapy, and frontline CD30-positive mature T-cell lymphoma in combination with chemotherapy, as well as in Phase I and II studies in various lymphoma and non-lymphoma indications. In addition, it is developing a pipeline of other clinical-stage programs, including SGN-CD19A for CD19A-positive hematologic malignancies; SGN-CD33A in CD33-positive acute myeloid leukemia; SGN-LIV1A in LIV-1-positive breast cancer; ASG-22ME for the treatment of Nectin-4-positive solid tumors; ASG-15ME for treatment of SLITRK6-positive bladder cancer; and SEA-CD40, a non-fucosylated antibody utilizing a novel immuno-oncology technology. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie, Bayer, Genentech, GlaxoSmithKline, and Pfizer. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

657 Employees
Last Reported Date: 02/27/15
Founded in 1998

seattle genetics inc (SGEN) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $759.3K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $422.1K
Chief Operating Officer
Total Annual Compensation: $472.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $448.0K
Executive Vice President of Technical Operati...
Total Annual Compensation: $378.4K
Compensation as of Fiscal Year 2014.

seattle genetics inc (SGEN) Key Developments

Seattle Genetics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Seattle Genetics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues were $82.2 million, compared to $68.3 million in the first quarter of 2014. Net loss was $21.7 million, or $0.17 per share, compared to a net loss of $16.3 million, or $0.13 per share, for the first quarter of 2014. Loss from operations was $21.743 million against $16.371 million a year ago.

FDA Accepts Supplemental BLA and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in the AETHERA Setting for the Post-Transplant Consolidation Treatment of Hodgkin Lymphoma Patients at High Risk of Relapse

Seattle Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) for ADCETRIS (brentuximab vedotin) in the AETHERA setting for the post-transplant consolidation treatment of Hodgkin lymphoma (HL) patients at high risk of relapse or progression. The FDA granted Priority Review for the application and the Prescription Drug User Fee Act (PDUFA) target action date is August 18, 2015. The submission of the supplemental BLA is based on positive results from a phase 3 clinical trial called AETHERA that was designed to determine if 16 cycles of ADCETRIS as consolidation therapy immediately following an autologous stem cell transplant (ASCT) could extend progression-free survival (PFS) in HL patients at high risk of relapse or progression. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma (sALCL), as well as other lymphoma subtypes. ADCETRIS is approved in relapsed HL and sALCL but is currently not approved for consolidation therapy in HL patients immediately after ASCT.

Seattle Genetics, Inc. to Report Q1, 2015 Results on Apr 30, 2015

Seattle Genetics, Inc. announced that they will report Q1, 2015 results at 1:30 PM, Pacific Standard Time on Apr 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGEN:US $34.20 USD +0.17

SGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $9.24 USD +0.09
Genmab A/S kr543.00 DKK +12.00
Insys Therapeutics Inc $54.75 USD +1.36
MorphoSys AG €65.32 EUR -2.18
Pfizer Ltd/India 2,241 INR +48.65
View Industry Companies
 

Industry Analysis

SGEN

Industry Average

Valuation SGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.1x
Price/Book 20.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEATTLE GENETICS INC, please visit www.seattlegenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.